Aphexda Injection, Powder, Lyophilized, For Solution
NDC Package 73441-062-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Aphexda (motixafortide) injection is aPHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Gamida Cell Inc., this product is identified by NDC 73441-062 and is authorized under FDA application NDA217159.

Identification & Billing

NDC Package Code
73441-062-01
Package Description
1 VIAL, GLASS in 1 CARTON / 1.7 mL in 1 VIAL, GLASS
Product Code
73441-062
11-Digit Billing Format
73441006201
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Aphexda
Non-Proprietary Name
Motixafortide
Substance Name
Motixafortide Acetate
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
MOTIXAFORTIDE ACETATE 62 mg/1.7mL
Usage Information
APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

Regulatory & Marketing

Labeler Name
Gamida Cell Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA217159
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-15-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J2277
Source: PDAC
INJECTION, MOTIXAFORTIDE, 0.25 MG
HCPCS Dosage 0.25 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73441-062-01 identifies a specific commercial package of 1 vial, glass in 1 carton / 1.7 ml in 1 vial, glass of Aphexda, a human prescription drug labeled by Gamida Cell Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This injection, powder, lyophilized, for solution is formulated for subcutaneous use and contains motixafortide acetate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gamida Cell Inc. on June 15, 2025. The current certification is valid through December 31, 2027.

How is this Gamida Cell Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73441006201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
73441-062-01
11-Digit CMS (5-4-2)
73441-0062-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.